Upexi, Inc.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US39959A1060

USD

2.85

-0.04 (-1.55%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chromadex Corp.

Nature's Sunshine Products, Inc.

LifeVantage Corp.

Upexi, Inc.

Natural Alternatives International, Inc.

ProPhase Labs, Inc.

USANA Health Sciences, Inc.

Revolution Medicines, Inc.

Cidara Therapeutics, Inc.

MIRA Pharmaceuticals, Inc.

Bright Green Corp.

Why is Upexi, Inc. ?

Poor Management Efficiency with a low ROCE of 2.46%

The company has been able to generate a Return on Capital Employed (avg) of 2.46% signifying low profitability per unit of total capital (equity and debt)

Flat results in Mar 25

With ROE of -616.52%, it has a risky valuation with a 229.66 Price to Book Value

Over the past year, while the stock has generated a return of -41.03%, its profits have risen by 28.2%

Majority shareholders : FIIs

Below par performance in long term as well as near term

Along with generating -41.03% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Upexi, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Upexi, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Upexi, Inc.

-36.53%

-0.19

368.76%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

24.53%

EBIT Growth (5y)

-217.23%

EBIT to Interest (avg)

-2.44

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

3.90

Sales to Capital Employed (avg)

2.12

Tax Ratio

11.97%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.63%

ROCE (avg)

2.46%

ROE (avg)

2.47%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

229.66

EV to EBIT

-38.26

EV to EBITDA

-44.95

EV to Capital Employed

47.70

EV to Sales

25.81

PEG Ratio

Dividend Yield

ROCE (Latest)

-124.67%

ROE (Latest)

-616.52%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -765.14% (YoY

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Upexi, Inc.

Raw Material Cost

Fallen by -765.14% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales